Botanical And Plant-Derived Drugs: Global Markets
February 17, 2009
Wellesley, Mass—According to a new technical market research report, BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS (BIO022E) from BCC Research (www.bccresearch.com), the global market for botanical and plant-derived drugs was worth $19.5 billion in 2008. This is expected to reach $32.9 billion in 2013, for a compound annual growth rate (CAGR) of 11.0%.
The market is broken down into botanical drugs and all other plant-derived drugs. Of these, plant-derived drugs have the largest share of the market, generating $19.5 billion in 2008. This is expected to increase to $30.5 billion in 2013, for a CAGR of 9.4%.
Botanical drugs were worth $127,000.00 in 2008, but this segment is expected to grow at a CAGR of 651.7% to reach $2.4 billion in 2013. Another way of thinking about this increase is to consider that one botanical product will translate into 12 approved drugs by 2013.
Some of these products may be approved for multiple indications during this time period. BCC projects the approved indications to reach a total of 14 by 2013 with oncology being the most prominent, followed by hormone and metabolism as a secondary therapeutic category.
![]()
The merits of plants and their extracts have been well known since ancient times. Evidence of plant-derived compounds taking on a more significant role in the pharmaceutical market today is the U.S. Food and Drug Administration’s carving out of a new drug approval pathway for botanical drugs in 2004, and approving the first botanical based on these guidelines in 2006.
Much more opportunity exists within the industry of plant-derived drugs. Consider that the number of higher plant species on earth is estimated around 350,000, with just 10%
Botanical and Plant-Derived Drugs: Global Markets( BIO022E )
Publish Date: Feb 2009
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum